Marker Therapeutics, Inc., a clinical-stage immunotherapy company, is making strides in the development and commercialization of T cell-based immunotherapies for the treatment of various types of cancer in the United States. The company's MultiTAA-specific T cell technology relies on the production of non-engineered tumor-specific T cells that are capable of recognizing and attacking multiple tumor-associated antigens. Among its portfolio of MultiTAA-specific T cell therapies are autologous T cells for treating lymphoma and select solid tumors, as well as allogeneic T cells for treating acute myeloid leukemia and acute lymphoblastic leukemia. It is also working on off-the-shelf products for various indications. Currently, Marker Therapeutics is in the middle of Phase 2 clinical trials for MT-401, a treatment for post-transplant AML; MT-401-OTS, AML; and MT-601, pancreatic cancer, and lymphoma. The company was established in 1999 and has been based in Houston, Texas ever since.
Marker Therapeutics, Inc.'s ticker is MRKR
The company's shares trade on the NASDAQ stock exchange
They are based in Houston, Texas
There are 11-50 employees working at Marker Therapeutics, Inc.
It is https://www.markertherapeutics.com/
Marker Therapeutics, Inc. is in the Healthcare sector
Marker Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Marker Therapeutics, Inc.'s industry peers: